FIELD: medicine. SUBSTANCE: method involves mixing solution fibrinogen precipitate/Factor XIII with thrombin under conditions providing inhibition of thrombin capability to form occlusions. This mixture is applied on body site under conditions influencing thrombin and converting fibrinogen to fibrin thickening agent. Syringe or one-single package can be used for administration of fibrin thickening agent. Invention can be used at different surgery operations in human and animals. EFFECT: improved method of administration. 14 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PROVIDING IMPROVED SEALING BY MEANS OF FIBRIN | 2011 |
|
RU2556960C2 |
| METHOD FOR UTILIZATION OF FIBRIN SEALING MATERIAL, METHOD OF PREPARING COMPOSITION, COMPOSITIONS, AND KITS | 1993 |
|
RU2143924C1 |
| ORGAN-SPECIFIC REGENERANT GI | 2011 |
|
RU2462255C1 |
| FIBRINOGEN CONTENT ANALYSIS | 2012 |
|
RU2619256C2 |
| HARD BANDAGE FOR TREATMENT OF INJURED TISSUE | 2007 |
|
RU2480191C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VIIA AND FACTOR XIII | 2001 |
|
RU2272648C2 |
| CRUSHED POLYMERIC HYDROGELS FOR PREVENTION OF COMMISSURE FORMATION AND METHODS FOR THEIR PREPARING | 1997 |
|
RU2207882C2 |
| COMPLEMENTED MATRIXES FOR TREATING BONE FRACTURES | 2006 |
|
RU2422172C2 |
| METHOD FOR DETERMINING FIBRINOGEN DURING RECALCIFICATION OF CITRATE PLASMA AND EVALUATING ITS FUNCTIONALITY | 2019 |
|
RU2703541C1 |
| METHOD FOR PRODUCING AUTOLOGOUS FIBRIN WITH CONTROLLED FIBRINOGEN CONTENT WITHOUT USING EXOGENOUS THROMBIN | 2020 |
|
RU2758260C1 |
